1,2-distearoyllecithin has been researched along with Leukemia P388 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bally, MB; Choi, L; Cullis, PR; de Jong, G; Longman, SA | 1 |
Krishna, R; Mayer, LD | 1 |
2 other study(ies) available for 1,2-distearoyllecithin and Leukemia P388
Article | Year |
---|---|
A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo.
Topics: Animals; Bacterial Proteins; Doxorubicin; Drug Carriers; Female; Flow Cytometry; Leukemia P388; Liposomes; Metabolic Clearance Rate; Mice; Mice, Inbred Strains; Microscopy, Fluorescence; Peritoneal Lavage; Phosphatidylcholines; Streptavidin | 1995 |
Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol; Cyclosporins; Doxorubicin; Drug Carriers; Drug Resistance, Multiple; Female; Leukemia P388; Liposomes; Metabolic Clearance Rate; Mice; Phosphatidylcholines; Tissue Distribution | 1997 |